Literature DB >> 19201903

Lactate boosts TLR4 signaling and NF-kappaB pathway-mediated gene transcription in macrophages via monocarboxylate transporters and MD-2 up-regulation.

Devadoss J Samuvel1, Kamala P Sundararaj, Alena Nareika, Maria F Lopes-Virella, Yan Huang.   

Abstract

It has been shown that lactate induces insulin resistance. However, the underlying mechanisms have not been well understood. Based on our observation that lactate augments LPS-stimulated inflammatory gene expression, we proposed that lactate may enhance TLR4 signaling in macrophages, which has been shown to play an important role in insulin resistance in adipocytes. In this study, we demonstrated that lactate stimulated MD-2, a coreceptor for TLR4 signaling activation, NF-kappaB transcriptional activity, and the expression of inflammatory genes in human U937 histiocytes (resident macrophages). Similar enhancement of the inflammatory gene expression by lactate was also observed in human monocyte-derived macrophages. The essential role of MD-2 in lactate-augmented TLR4 signaling was confirmed by observation that the suppression of MD-2 expression by small interfering RNA led to significant inhibition of inflammatory gene expression. To further elucidate how lactate treatment enhances TLR4 activation, we showed that the augmentation of inflammatory gene expression by lactate was abrogated by antioxidant treatment, suggesting a critical role of reactive oxygen species in the enhancement of TLR4 activation by lactate. Finally, we showed that alpha-cyano-4-hydroxycinnamic acid, a classic inhibitor for monocarboxylate transporters, blocked lactate-augmented inflammatory gene expression and nuclear NF-kappaB activity, indicating that lactate transport through monocarboxylate transporters is required for lactate-enhanced TLR4 activation. Collectively, this study documents that lactate boosts TLR4 activation and NF-kappaB-dependent inflammatory gene expression via monocarboxylate transporters and MD-2 up-regulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201903      PMCID: PMC2673542          DOI: 10.4049/jimmunol.0802059

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins.

Authors:  Carey N Lumeng; Stephanie M Deyoung; Alan R Saltiel
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-08-22       Impact factor: 4.310

2.  Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study.

Authors:  Chaim B Colen; Navid Seraji-Bozorgzad; Brian Marples; Matthew P Galloway; Andrew E Sloan; Saroj P Mathupala
Journal:  Neurosurgery       Date:  2006-12       Impact factor: 4.654

Review 3.  Role of cAMP response element binding protein in cardiovascular remodeling: good, bad, or both?

Authors:  Toshihiro Ichiki
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-11-17       Impact factor: 8.311

4.  TLR4 links innate immunity and fatty acid-induced insulin resistance.

Authors:  Hang Shi; Maia V Kokoeva; Karen Inouye; Iphigenia Tzameli; Huali Yin; Jeffrey S Flier
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

5.  Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes.

Authors:  Min Jeong Song; Kang Ho Kim; Jeong Min Yoon; Jae Bum Kim
Journal:  Biochem Biophys Res Commun       Date:  2006-06-06       Impact factor: 3.575

6.  Lactate treatment causes NF-kappaB activation and CD44 shedding in cultured trabecular meshwork cells.

Authors:  Adam M Miller; Michael J Nolan; John Choi; Tomoyo Koga; Xiang Shen; Beatrice Y J T Yue; Paul A Knepper
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-04       Impact factor: 4.799

7.  Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity.

Authors:  Francis Kim; Matilda Pham; Ian Luttrell; Douglas D Bannerman; Joan Tupper; Joshua Thaler; Thomas R Hawn; Elaine W Raines; Michael W Schwartz
Journal:  Circ Res       Date:  2007-05-03       Impact factor: 17.367

Review 8.  Antioxidants: do they have a role in the treatment of insulin resistance?

Authors:  Joseph L Evans
Journal:  Indian J Med Res       Date:  2007-03       Impact factor: 2.375

9.  Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance.

Authors:  Daniela M L Tsukumo; Marco A Carvalho-Filho; José B C Carvalheira; Patrícia O Prada; Sandro M Hirabara; André A Schenka; Eliana P Araújo; José Vassallo; Rui Curi; Lício A Velloso; Mario J A Saad
Journal:  Diabetes       Date:  2007-05-22       Impact factor: 9.461

10.  C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet.

Authors:  M Poggi; D Bastelica; P Gual; M A Iglesias; T Gremeaux; C Knauf; F Peiretti; M Verdier; I Juhan-Vague; J F Tanti; R Burcelin; M C Alessi
Journal:  Diabetologia       Date:  2007-04-11       Impact factor: 10.122

View more
  59 in total

Review 1.  Extrinsic and intrinsic control of macrophage inflammatory responses.

Authors:  Heather B Cohen; David M Mosser
Journal:  J Leukoc Biol       Date:  2013-08-20       Impact factor: 4.962

2.  Lactate reduces liver and pancreatic injury in Toll-like receptor- and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity.

Authors:  Rafaz Hoque; Ahmad Farooq; Ayaz Ghani; Fred Gorelick; Wajahat Zafar Mehal
Journal:  Gastroenterology       Date:  2014-03-20       Impact factor: 22.682

3.  Lactate Dehydrogenase Inhibition With Oxamate Exerts Bone Anabolic Effect.

Authors:  Alex M Hollenberg; Charles O Smith; Laura C Shum; Hani Awad; Roman A Eliseev
Journal:  J Bone Miner Res       Date:  2020-09-19       Impact factor: 6.741

4.  MD-2 is involved in the stimulation of matrix metalloproteinase-1 expression by interferon-γ and high glucose in mononuclear cells - a potential role of MD-2 in Toll-like receptor 4-independent signalling.

Authors:  Zhongyang Lu; Yanchun Li; Devadoss J Samuvel; Junfei Jin; Xiaoming Zhang; Maria F Lopes-Virella; Yan Huang
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

5.  Metabolites of Lactobacillus plantarum 2142 prevent oxidative stress-induced overexpression of proinflammatory cytokines in IPEC-J2 cell line.

Authors:  Erzsebet Paszti-Gere; Krisztina Szeker; Edina Csibrik-Nemeth; Rita Csizinszky; Andras Marosi; Orsolya Palocz; Orsolya Farkas; Peter Galfi
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

6.  Enhanced glycolytic metabolism supports transmigration of brain-infiltrating macrophages in multiple sclerosis.

Authors:  Deepak Kumar Kaushik; Anindita Bhattacharya; Reza Mirzaei; Khalil S Rawji; Younghee Ahn; Jong M Rho; V Wee Yong
Journal:  J Clin Invest       Date:  2019-05-21       Impact factor: 14.808

7.  The monocarboxylate transporter 4 is required for glycolytic reprogramming and inflammatory response in macrophages.

Authors:  Zheng Tan; Na Xie; Sami Banerjee; Huachun Cui; Mingui Fu; Victor J Thannickal; Gang Liu
Journal:  J Biol Chem       Date:  2014-11-18       Impact factor: 5.157

8.  Enhanced Glycolytic Metabolism Contributes to Cardiac Dysfunction in Polymicrobial Sepsis.

Authors:  Zhibo Zheng; He Ma; Xia Zhang; Fei Tu; Xiaohui Wang; Tuanzhu Ha; Min Fan; Li Liu; Jingjing Xu; Kaijiang Yu; Ruitao Wang; John Kalbfleisch; Race Kao; David Williams; Chuanfu Li
Journal:  J Infect Dis       Date:  2017-05-01       Impact factor: 5.226

9.  Hexokinase II binding to mitochondria is necessary for Kupffer cell activation and is potentiated by ethanol exposure.

Authors:  Nataly Shulga; John G Pastorino
Journal:  J Biol Chem       Date:  2014-08-05       Impact factor: 5.157

Review 10.  Inflammatory mediators in mastitis and lactation insufficiency.

Authors:  Wendy V Ingman; Danielle J Glynn; Mark R Hutchinson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-06-25       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.